63 related articles for article (PubMed ID: 11243403)
1. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Al-Modhwahi I; Andersen MK; Behrendtz M; Forestier E; Hasle H; Heyman M; Kristinsson J; Nersting J; Nygaard R; Svendsen AL; Vettenranta K; Weinshilboum R;
Blood; 2009 Jun; 113(24):6077-84. PubMed ID: 19224761
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic metabolism presenting as a recalcitrant case of hand-foot syndrome and mucositis.
Kwan KR; Skokan S; Blesh-Boren T; Vogel J; Harter N; Ford JB
J Oncol Pharm Pract; 2024 Apr; 30(3):584-588. PubMed ID: 38204187
[TBL] [Abstract][Full Text] [Related]
4. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia.
Hijiya N; Panetta JC; Zhou Y; Kyzer EP; Howard SC; Jeha S; Razzouk BI; Ribeiro RC; Rubnitz JE; Hudson MM; Sandlund JT; Pui CH; Relling MV
Blood; 2006 Dec; 108(13):3997-4002. PubMed ID: 16917005
[TBL] [Abstract][Full Text] [Related]
5. Maintenance Treatment in Acute Lymphoblastic Leukemia: A Clinical Primer.
Krishnan S; Mahadevan A; Mungle T; Gogoi MP; Saha V
Indian J Pediatr; 2024 Jan; 91(1):47-58. PubMed ID: 37493925
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence study followed by model-informed dose optimization of a powder for oral suspension of 6-mercaptopurine.
Arun B; Joshi M; Kakkar AK; Madki S; Ivaturi V; Chinnaswamy G; Banavali S; Gota V
Pediatr Blood Cancer; 2024 Mar; 71(3):e30813. PubMed ID: 38110844
[TBL] [Abstract][Full Text] [Related]
7. The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia.
Liao C; Nie J; Xu XJ; Zhang JY; Xu WQ; Song H; Shen HP; Shen DY; Zhao FY; Liang J; Miao J; Tang YM
Leuk Lymphoma; 2024 Jan; 65(1):91-99. PubMed ID: 37820046
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia.
Singh M; Bhaskar D; Bhatia P; Thakur R; Sharma P; Bansal D; Jain R; Trehan A
Cancer Chemother Pharmacol; 2023 Jul; 92(1):51-56. PubMed ID: 37256334
[TBL] [Abstract][Full Text] [Related]
9. Assessment on the use of allopurinol to improve safety and efficacy of mercaptopurine in pediatric patients with Acute Lymphoblastic Leukemia and Lymphoma during maintenance therapy.
Barone T; Dandekar S; McKeone D; Mulieri K
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1987. PubMed ID: 38351548
[TBL] [Abstract][Full Text] [Related]
10. Oral Mercaptopurine Adherence in Pediatric Acute Lymphoblastic Leukemia: A Survey Study From the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium.
Kahn JM; Stevenson K; Beauchemin M; Koch VB; Cole PD; Welch JJG; Gage-Bouchard E; Karsenty C; Silverman LB; Kelly KM; Bona K
J Pediatr Hematol Oncol Nurs; 2023; 40(1):17-23. PubMed ID: 36221984
[No Abstract] [Full Text] [Related]
11. Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children With Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Bhatia S; Hageman L; Chen Y; Wong FL; McQuaid EL; Duncan C; Mascarenhas L; Freyer D; Mba N; Aristizabal P; Walterhouse D; Lew G; Kempert PH; Russell TB; McNall-Knapp RY; Jacobs S; Dang H; Raetz E; Relling MV; Landier W
JAMA Netw Open; 2020 Aug; 3(8):e2014205. PubMed ID: 32852553
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian joint model for multivariate longitudinal and time-to-event data with application to ALL maintenance studies.
Kundu D; Sarkar P; Gogoi MP; Das K
J Biopharm Stat; 2024 Jan; 34(1):37-54. PubMed ID: 36882959
[TBL] [Abstract][Full Text] [Related]
13. [Adverse effects of high-dose methotrexate therapy].
Sun Q; Xie Y; Zhao WH; Hua Y; Wu PH; Li S; Lu XT
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Jul; 19(7):781-785. PubMed ID: 28697831
[TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
Chen X; Li J; Yu L; Hu W; Cai J; Wang Z; Chen C; Zhang X; Xie Y; Wu K; Mo Y; Chen J; Shen S
Br J Haematol; 2024 Apr; 204(4):1354-1366. PubMed ID: 38432257
[TBL] [Abstract][Full Text] [Related]
15. DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship?
Harju T; Hurme-Niiranen A; Suo-Palosaari M; Nygaard Nielsen S; Hinttala R; Schmiegelow K; Uusimaa J; Harila A; Niinimäki R
Pharmacogenomics J; 2023 Sep; 23(5):105-111. PubMed ID: 37138020
[TBL] [Abstract][Full Text] [Related]
16. A Rare Case of Acute Methotrexate Toxicity Leading to Bone Marrow Suppression.
Khuwaja S; Lyons M; Zulfiqar B
Case Rep Rheumatol; 2024; 2024():7693602. PubMed ID: 38523896
[TBL] [Abstract][Full Text] [Related]
17. A novel turn-on fluorescence sensor based on the Nd (III) complex for the ultrasensitive detection of 6-mercaptopurine.
Rajpal ; Jana S; Ojha RP; Prakash R
Spectrochim Acta A Mol Biomol Spectrosc; 2024 May; 313():124056. PubMed ID: 38447438
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and risk factors of acute lymphoblastic leukemia in children with severe infection during maintenance treatment.
Yin T; Han J; Hao J; Yu H; Qiu Y; Xu J; Peng Y; Wu X; Jin R; Zhou F
Cancer Med; 2023 Oct; 12(19):19372-19382. PubMed ID: 37768027
[TBL] [Abstract][Full Text] [Related]
19. Hybrid Email and Outpatient Clinics to Optimize Maintenance Therapy in Acute Lymphoblastic Leukemia.
Mungle T; Mahadevan A; Das P; Mehta AK; Gogoi MP; Jana B; Ghara N; Ghosh D; Saha V; Krishnan S
J Pediatr Hematol Oncol; 2024 Jan; 46(1):39-45. PubMed ID: 38096154
[TBL] [Abstract][Full Text] [Related]
20. Delayed presentation of vincristine extravasation.
Ghaffary S; Gholami N; Samankan S; Pourkarim F
J Oncol Pharm Pract; 2023 Dec; 29(8):2023-2026. PubMed ID: 37475540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
